CRISPR Therapeutics and Sirius Therapeutics Collaborate on New siRNA Therapies Targeting Thrombotic Diseases
Monday, May 19, 2025
CRISPR Therapeutics has entered a strategic partnership with Sirius Therapeutics.
The collaboration aims to develop and bring to market novel siRNA treatments, focusing on cardiovascular conditions.
The partnership will focus on SRSD107, a next-generation siRNA therapy designed to selectively inhibit Coagulation Factor XI (FXI). FXI plays a crucial role in pathological thrombosis but has a limited effect on normal blood clotting. Targeting FXI offers a potential treatment for thrombotic diseases while reducing the risk of bleeding, which is a common concern with current therapies.
SRSD107 is designed for long-lasting effects, allowing for infrequent dosing through subcutaneous injections, potentially every six months. This treatment could benefit patients at risk of thromboembolic events due to conditions such as atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, chronic coronary and peripheral vascular diseases, end-stage renal disease requiring dialysis, and those undergoing major orthopaedic surgery.
Early clinical trials have shown promising results. Phase 1 studies demonstrated that single doses of SRSD107 were safe and well tolerated. The therapy produced strong pharmacodynamic effects, reducing FXI levels and activity by over 90%, and extending blood clotting times. These effects lasted for up to six months after dosing.
The collaboration combines CRISPR Therapeutics’ gene-editing expertise with Sirius Therapeutics’ siRNA technology, expanding their combined capabilities to develop new treatments for serious thrombotic conditions.
The ongoing clinical development of SRSD107 is expected to further evaluate its safety and efficacy in patients.
Source: crisprtx.com
